Loma Linda University

GION study evaluates KUS121 intravitreal injection efficacy and safety in acute non-arteritic CRAO. Interventions include KUS121 high and low doses, and a sham procedure. Sponsored by Kyoto Drug Discovery & Development Co., Ltd.

Join The Kensington Falls Church and Neurologist Jennifer Pauldurai, MD of Inova for an event on Alzheimer’s treatment, including the FDA-approved Donanemab. The session will also cover managing behavioral symptoms like stress, agitation, and mood changes, providing practical strategies for caregivers and loved ones.